Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | HMGCR | P04035 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.40 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL4564860 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27231788 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28709235 | 0.95 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8820192 | 0.93 | ALDH1A1 (0.71) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3417188 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1331942 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL240402 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10896997 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL842 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL725546 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390284-A1 | DEGRADANT COMPOUND IN A MEDICANT | VISUS THERAPEUTICS, INC. | 2023-12-07 | — | — | US | claimed |
| CN-116712399-A | Preparation process of capsule for treating multiple myeloma proteasome inhibitor | 浙江美华鼎昌医药科技有限公司 | 2023-09-08 | — | — | CN | claimed |
| EP-4236932-A1 | DEGRADANT COMPOUND IN A MEDICAMENT | Visus Therapeutics, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116583277-A | Degradation compounds in pharmaceuticals | 视觉治疗股份有限公司 | 2023-08-11 | — | — | CN | claimed |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN INC (US) | 2023-08-03 | — | — | US | claimed |
| WO-2023086878-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | VISUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4003246-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRESBYOPIA | Allergan, Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| EP-4003341-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRESBYOPIA | Allergan Sales, LLC (US) | 2022-06-01 | — | — | EP | claimed |
| WO-2022094462-A1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| CN-114269301-A | Compositions and methods for treating presbyopia | 阿勒根公司 | 2022-04-01 | — | — | CN | claimed |
| US-20130005665-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN, INC. | 2013-01-03 | — | — | US | claimed |
| WO-2013003827-A2 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | WO | claimed |
| US-20080213353-A1 | Liposomes encapsulate active agent; vehicles for the delivery of drugs and active agents as well as in the field of gene transfer; delayed, sustained or prolonged release, gradual release, timed release, pH dependent release | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-09-04 | — | — | US | claimed |
| EP-1585771-A4 | COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS | ALTUS PHARMACEUTICALS INC (US) | 2006-11-29 | — | — | EP | claimed |
| US-20060165766-A1 | Liposomes encapsulate active agent; vehicles for the delivery of drugs and active agents as well as in the field of gene transfer; delayed, sustained or prolonged release, gradual release, timed release, pH dependent release | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-07-27 | — | — | US | claimed |
| US-20060008532-A1 | Complexes of protein crystals and ionic polymers | ALTHEA TECHNOLOGIES, INC. | 2006-01-12 | — | — | US | claimed |
| EP-1585771-A1 | COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS | Altus Pharmaceuticals Inc. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2004060920-A1 | COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS | ALTUS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1429726-A2 | A METHOD FOR PREPARING LIPOSOME FORMULATIONS WITH A PREDEFINED RELEASE PROFILE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-06-23 | — | — | EP | claimed |
| WO-2003032947-A2 | A METHOD FOR PREPARING LIPOSOME FORMULATIONS WITH A PREDEFINED RELEASE PROFILE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-04-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213353-A1 | Liposomes encapsulate active agent; vehicles for the delivery of drugs and active agents as well as in the field of gene transfer; delayed, sustained or prolonged release, gradual release, timed release, pH dependent release | LIPA, SLC47A1, CTSA | MEN1 2493/4885ALDH1A1 3205/4885HMGCR 2006/4885 |
| US-20060165766-A1 | Liposomes encapsulate active agent; vehicles for the delivery of drugs and active agents as well as in the field of gene transfer; delayed, sustained or prolonged release, gradual release, timed release, pH dependent release | LIPA, SLC47A1, CTSA | MEN1 2493/4885ALDH1A1 3205/4885HMGCR 2006/4885 |
| US-20130005665-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | LIPA, CYP27A1, HSD17B13 | MEN1 234/4885ALDH1A1 2683/4885HMGCR 8/4885 |
| US-20230390284-A1 | DEGRADANT COMPOUND IN A MEDICANT | CHRM2, CHRM5, CHRM3 | MEN1 261/4885ALDH1A1 3755/4885HMGCR 679/4885 |
| US-20230241030-A1 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS | LIPA, CYP27A1, HSD17B13 | MEN1 234/4885ALDH1A1 2683/4885HMGCR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.